Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialJie Wang, Qiming Wang, Xuhong Min et al.|The Lancet Oncology|2022Cited by 417
EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosisFei Xu, Tong-Yu Lin|Chinese Journal of Cancer|2011Cited by 15